Labcorp Holdings Inc.

Company facts

Industry

Services-Medical Laboratories

Headquarters

Burlington, North Carolina

Most recent report

8-K, filed Nov 4, 2026

Incorporated

N/A

Filings on record

1,002+ filings

On EDGAR

CIK 920148

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 4 of 13 sections worth reading, with 2 positive, 11 notable, and 3 negative flags.

• Financial Statements (Item 1)

  Financial statements and notes with acquisition pipeline, debt restructuring, and litigation details.
  Notable

  • Four post-quarter acquisitions announced for up to $1.6B total: BioReference ($872M), Myriad Prenatal ($210M), Millennium Health ($375M).
  • Goodwill rose $387.5M to $7.18B, mostly from acquisitions; $648.5M cumulative impairment already recorded in BLS.
  • New $750M term loan due 2028 used to redeem $500M 1.55% senior notes due 2026; total debt rose to $5.85B.
  • AR Facility increased from $300M to $700M, extended to Jan 2029; $556M drawn at Sept 30, 2026.
  • Board authorized $1B additional buyback on July 8, 2026; $451.8M spent in nine months vs $225M a year ago.
  Negative

  • Jury awarded $272M for patent infringement; court added $100M enhanced damages; appeal scheduled Dec 2026.

• Management's Discussion (Item 2)

  Full MD&A with segment results, cash flows, debt, and three new acquisitions.
  Positive

  • Revenue up 6.9% to $3,810.0M in Q3 2026, with organic growth of 5.5%.
  Notable

  • Cash and equivalents fell to $261.8M at Sep 30, 2026 from $598.1M a year earlier.
  • Capital expenditures rose to $404.2M for nine months ended Sep 30, 2026, from $310.6M.
  • Board authorized $1,000M additional share repurchase on July 8, 2026; $1,378.6M remaining.
  • Noncancelable purchase commitment of $111.5M for supplies inventory through 2028.
  • Company expects to refinance $600M 3.60% senior notes due Sep 2027 at higher rates.

• Item 1A

  New ERP implementation risk with quantified cash flow impact; supplements annual report.
  Negative

  • New ERP system deployment may force accelerated inventory buys, directly harming cash flows and liquidity.
  • ERP integration is complex and could disrupt supply chain, procurement, and transaction processing.

• Management's Discussion (Item 2)

  New $1B buyback authorization; no shares bought in Q3 2026.
  Positive

  • New $1.0B buyback authorization on July 8, 2026; total remaining $1.3786B.
  Notable

  • No shares repurchased in Q3 2026, despite prior authorization.

What changed: Sep 2026 vs. Jun 2026

About 8% of LH's Sep 2026 10-Q is new information. 26 paragraphs were added, 150 changed, and 19 removed. Below are the most important lines SECSift identified.

• Item 2 68
• Item 1 43
• Part II 6
• Item 3 5
• Item 1A 4
• Item 5 3
• Item 4 2